Cargando…
Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently FDA-approved...
Autores principales: | Hooper, Candace Y, Smith, Winter J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333464/ https://www.ncbi.nlm.nih.gov/pubmed/22547931 http://dx.doi.org/10.2147/TCRM.S23247 |
Ejemplares similares
-
Predictors of Clinical Success in the Treatment of Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP)
por: Shorr, Andrew F., et al.
Publicado: (2015) -
Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy
por: Pletz, Mathias W, et al.
Publicado: (2010) -
Lower Methicillin-Resistant Staphylococcus aureus (MRSA) Acquisition and Nosocomial Cultures While on Anti-MRSA Antibiotics?
por: Jones, Makoto, et al.
Publicado: (2015) -
Epidemiology and Outcome of Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals
por: Tadros, Manal, et al.
Publicado: (2013) -
Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia
por: Jung, Won Jai, et al.
Publicado: (2013)